Roche Bulks Up In NLRP3 With €380m Inflazome Buy
Irish Biotech A Pioneer In Inflammasomes
Executive Summary
Having acquired Jecure Therapeutics and its preclinical portfolio of NLRP3 inhibitors just under two years ago, the Swiss giant has swooped in to buy Dublin-based Inflazome and expand its presence in a hot field of inflammatory research.
You may also be interested in...
Roche’s COVID-19 Collaboration Strategy Sees Promise In Combinations
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
Ireland's Fountain Closes €125m Life Sciences Fund
The Dublin-based venture capital group will be looking to replicate the success of portfolio companies Inflazome and KaNDy, recently acquired by Roche and Bayer respectively, with the biotechs backed from its latest fund.
Finding The Exit: Forbion On Roche’s Acquisition Of Inflazome
Two years after leading a $46m series B financing round in Inflazome, a four-year old Irish biotech developing oral NLRP3 inflammasome inhibitors, VC firm Forbion is celebrating Roche’s $446m acquisition of the company, which includes the potential for additional milestone payments. Forbion general partner Marco Boorsa, who joined Inflazome’s board of directors in November 2018, spoke with In Vivo about the VC firm’s investment strategy.